In an unusual partnership, health care rivals Allegheny Health Network and UPMC are collaborating with Vitalant in a pilot program to treat patients with severe cases of COVID-19 with blood plasma donated by people who have recovered from the highly infectious disease.
Vitalant, formerly the Central Blood Bank, is working with AHN and UPMC to collect what is known as convalescent plasma, which contains antibodies that are believed to be helpful in battling the disease. There are no approved vaccines or medicines to treat COVID-19.
Both AHN and UPMC have obtained Food and Drug Administration clearance to transfuse convalescent plasma into patients who are seriously ill with COVID-19. Vitalant will work with both AHN and UPMC to collect and process the plasma.
Donors, who have to show through testing that they are not currently sick with COVID-19, can enroll through Vitalant’s website or by emailing AHN at c2p3@ahn.org or UPMC at c2p3@upmc.edu.
“At this critical moment in the pandemic, it is truly remarkable to see physicians, hospitals, laboratories, our blood bank — and the very patients who recovered — working together on this new therapy,” Joseph Kiss, medical director of clinical apheresis and blood services at Vitalant, said in a statement.
Health care giants AHN and UPMC have been bitter rivals for many years. The fallout began when UPMC claimed that AHN’s parent, Highmark, was underpaying UPMC for treating people with Highmark health insurance.
Read More
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.
width:996px;margin:auto;overflow:hidden;cursor:pointer;">
This story was originally published with images that are no longer available.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.